Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women

Purpose To assess the effect of different treatment strategies on the risk of subsequent invasive breast cancer (IBC) in women diagnosed with ductal carcinoma in situ (DCIS). Methods Up to 15-year cumulative incidences of ipsilateral IBC (iIBC) and contralateral IBC (cIBC) were assessed among a popu...

Full description

Saved in:
Bibliographic Details
Published inBreast cancer research and treatment Vol. 159; no. 3; pp. 553 - 563
Main Authors Elshof, Lotte E., Schaapveld, Michael, Schmidt, Marjanka K., Rutgers, Emiel J., van Leeuwen, Flora E., Wesseling, Jelle
Format Journal Article
LanguageEnglish
Published New York Springer US 01.10.2016
Springer
Springer Nature B.V
Subjects
Aged
Breast cancer
Breast Neoplasms - epidemiology
Breast Neoplasms - radiotherapy
Breast Neoplasms - surgery
Cancer research
Cancer therapies
Cancer treatment
Carcinoma
Carcinoma, Ductal, Breast - epidemiology
Carcinoma, Intraductal, Noninfiltrating - radiotherapy
Carcinoma, Intraductal, Noninfiltrating - surgery
Cohort Studies
College football
Disease-Free Survival
Drug therapy
Epidemiology
Female
Health aspects
Humans
Incidence
Mastectomy - adverse effects
Mastectomy - methods
Mastectomy, Segmental - adverse effects
Mastectomy, Segmental - methods
Medicine
Medicine & Public Health
Middle Aged
Multimodal Imaging
Netherlands - epidemiology
Oncology
Proportional Hazards Models
Radiation therapy
Radiotherapy
Risk factors
Treatment Outcome
Women
Invasive breast cancer
Ductal carcinoma in situ
Radiotherapy
Surgery
Population-based cohort study
Online AccessGet full text
ISSN0167-6806
1573-7217
1573-7217
DOI10.1007/s10549-016-3973-y

Cover

Abstract Purpose To assess the effect of different treatment strategies on the risk of subsequent invasive breast cancer (IBC) in women diagnosed with ductal carcinoma in situ (DCIS). Methods Up to 15-year cumulative incidences of ipsilateral IBC (iIBC) and contralateral IBC (cIBC) were assessed among a population-based cohort of 10,090 women treated for DCIS in the Netherlands between 1989 and 2004. Multivariable Cox regression analyses were used to evaluate associations of treatment with iIBC risk. Results Fifteen years after DCIS diagnosis, cumulative incidence of iIBC was 1.9 % after mastectomy, 8.8 % after BCS+RT, and 15.4 % after BCS alone. Patients treated with BCS alone had a higher iIBC risk than those treated with BCS+RT during the first 5 years after treatment. This difference was less pronounced for patients <50 years [hazard ratio (HR) 2.11, 95 % confidence interval (CI) 1.35–3.29 for women <50, and HR 4.44, 95 % CI 3.11–6.36 for women ≥50, P interaction  < 0.0001]. Beyond 5 years of follow-up, iIBC risk did not differ between patients treated with BCS+RT or BCS alone for women <50. Cumulative incidence of cIBC at 15 years was 6.4 %, compared to 3.4 % in the general population. Conclusions We report an interaction of treatment with age and follow-up period on iIBC risk, indicating that the benefit of RT seems to be smaller among younger women, and stressing the importance of clinical studies with long follow-up. Finally, the low cIBC risk does not justify contralateral prophylactic mastectomies for many women with unilateral DCIS.
AbstractList To assess the effect of different treatment strategies on the risk of subsequent invasive breast cancer (IBC) in women diagnosed with ductal carcinoma in situ (DCIS). Up to 15-year cumulative incidences of ipsilateral IBC (iIBC) and contralateral IBC (cIBC) were assessed among a population-based cohort of 10,090 women treated for DCIS in the Netherlands between 1989 and 2004. Multivariable Cox regression analyses were used to evaluate associations of treatment with iIBC risk. Fifteen years after DCIS diagnosis, cumulative incidence of iIBC was 1.9 % after mastectomy, 8.8 % after BCS+RT, and 15.4 % after BCS alone. Patients treated with BCS alone had a higher iIBC risk than those treated with BCS+RT during the first 5 years after treatment. This difference was less pronounced for patients <50 years [hazard ratio (HR) 2.11, 95 % confidence interval (CI) 1.35-3.29 for women <50, and HR 4.44, 95 % CI 3.11-6.36 for women ≥50, P interaction  < 0.0001]. Beyond 5 years of follow-up, iIBC risk did not differ between patients treated with BCS+RT or BCS alone for women <50. Cumulative incidence of cIBC at 15 years was 6.4 %, compared to 3.4 % in the general population. We report an interaction of treatment with age and follow-up period on iIBC risk, indicating that the benefit of RT seems to be smaller among younger women, and stressing the importance of clinical studies with long follow-up. Finally, the low cIBC risk does not justify contralateral prophylactic mastectomies for many women with unilateral DCIS.
Purpose To assess the effect of different treatment strategies on the risk of subsequent invasive breast cancer (IBC) in women diagnosed with ductal carcinoma in situ (DCIS). Methods Up to 15-year cumulative incidences of ipsilateral IBC (iIBC) and contralateral IBC (cIBC) were assessed among a population-based cohort of 10,090 women treated for DCIS in the Netherlands between 1989 and 2004. Multivariable Cox regression analyses were used to evaluate associations of treatment with iIBC risk. Results Fifteen years after DCIS diagnosis, cumulative incidence of iIBC was 1.9 % after mastectomy, 8.8 % after BCS+RT, and 15.4 % after BCS alone. Patients treated with BCS alone had a higher iIBC risk than those treated with BCS+RT during the first 5 years after treatment. This difference was less pronounced for patients <50 years [hazard ratio (HR) 2.11, 95 % confidence interval (CI) 1.35-3.29 for women <50, and HR 4.44, 95 % CI 3.11-6.36 for women [greater than or equal to]50, P interaction < 0.0001]. Beyond 5 years of follow-up, iIBC risk did not differ between patients treated with BCS+RT or BCS alone for women <50. Cumulative incidence of cIBC at 15 years was 6.4 %, compared to 3.4 % in the general population. Conclusions We report an interaction of treatment with age and follow-up period on iIBC risk, indicating that the benefit of RT seems to be smaller among younger women, and stressing the importance of clinical studies with long follow-up. Finally, the low cIBC risk does not justify contralateral prophylactic mastectomies for many women with unilateral DCIS.
To assess the effect of different treatment strategies on the risk of subsequent invasive breast cancer (IBC) in women diagnosed with ductal carcinoma in situ (DCIS).PURPOSETo assess the effect of different treatment strategies on the risk of subsequent invasive breast cancer (IBC) in women diagnosed with ductal carcinoma in situ (DCIS).Up to 15-year cumulative incidences of ipsilateral IBC (iIBC) and contralateral IBC (cIBC) were assessed among a population-based cohort of 10,090 women treated for DCIS in the Netherlands between 1989 and 2004. Multivariable Cox regression analyses were used to evaluate associations of treatment with iIBC risk.METHODSUp to 15-year cumulative incidences of ipsilateral IBC (iIBC) and contralateral IBC (cIBC) were assessed among a population-based cohort of 10,090 women treated for DCIS in the Netherlands between 1989 and 2004. Multivariable Cox regression analyses were used to evaluate associations of treatment with iIBC risk.Fifteen years after DCIS diagnosis, cumulative incidence of iIBC was 1.9 % after mastectomy, 8.8 % after BCS+RT, and 15.4 % after BCS alone. Patients treated with BCS alone had a higher iIBC risk than those treated with BCS+RT during the first 5 years after treatment. This difference was less pronounced for patients <50 years [hazard ratio (HR) 2.11, 95 % confidence interval (CI) 1.35-3.29 for women <50, and HR 4.44, 95 % CI 3.11-6.36 for women ≥50, P interaction < 0.0001]. Beyond 5 years of follow-up, iIBC risk did not differ between patients treated with BCS+RT or BCS alone for women <50. Cumulative incidence of cIBC at 15 years was 6.4 %, compared to 3.4 % in the general population.RESULTSFifteen years after DCIS diagnosis, cumulative incidence of iIBC was 1.9 % after mastectomy, 8.8 % after BCS+RT, and 15.4 % after BCS alone. Patients treated with BCS alone had a higher iIBC risk than those treated with BCS+RT during the first 5 years after treatment. This difference was less pronounced for patients <50 years [hazard ratio (HR) 2.11, 95 % confidence interval (CI) 1.35-3.29 for women <50, and HR 4.44, 95 % CI 3.11-6.36 for women ≥50, P interaction < 0.0001]. Beyond 5 years of follow-up, iIBC risk did not differ between patients treated with BCS+RT or BCS alone for women <50. Cumulative incidence of cIBC at 15 years was 6.4 %, compared to 3.4 % in the general population.We report an interaction of treatment with age and follow-up period on iIBC risk, indicating that the benefit of RT seems to be smaller among younger women, and stressing the importance of clinical studies with long follow-up. Finally, the low cIBC risk does not justify contralateral prophylactic mastectomies for many women with unilateral DCIS.CONCLUSIONSWe report an interaction of treatment with age and follow-up period on iIBC risk, indicating that the benefit of RT seems to be smaller among younger women, and stressing the importance of clinical studies with long follow-up. Finally, the low cIBC risk does not justify contralateral prophylactic mastectomies for many women with unilateral DCIS.
To assess the effect of different treatment strategies on the risk of subsequent invasive breast cancer (IBC) in women diagnosed with ductal carcinoma in situ (DCIS). Up to 15-year cumulative incidences of ipsilateral IBC (iIBC) and contralateral IBC (cIBC) were assessed among a population-based cohort of 10,090 women treated for DCIS in the Netherlands between 1989 and 2004. Multivariable Cox regression analyses were used to evaluate associations of treatment with iIBC risk. Fifteen years after DCIS diagnosis, cumulative incidence of iIBC was 1.9 % after mastectomy, 8.8 % after BCS+RT, and 15.4 % after BCS alone. Patients treated with BCS alone had a higher iIBC risk than those treated with BCS+RT during the first 5 years after treatment. This difference was less pronounced for patients <50 years [hazard ratio (HR) 2.11, 95 % confidence interval (CI) 1.35-3.29 for women <50, and HR 4.44, 95 % CI 3.11-6.36 for women greater than or equal to 50, P interaction < 0.0001]. Beyond 5 years of follow-up, iIBC risk did not differ between patients treated with BCS+RT or BCS alone for women <50. Cumulative incidence of cIBC at 15 years was 6.4 %, compared to 3.4 % in the general population. We report an interaction of treatment with age and follow-up period on iIBC risk, indicating that the benefit of RT seems to be smaller among younger women, and stressing the importance of clinical studies with long follow-up. Finally, the low cIBC risk does not justify contralateral prophylactic mastectomies for many women with unilateral DCIS.
Purpose To assess the effect of different treatment strategies on the risk of subsequent invasive breast cancer (IBC) in women diagnosed with ductal carcinoma in situ (DCIS). Methods Up to 15-year cumulative incidences of ipsilateral IBC (iIBC) and contralateral IBC (cIBC) were assessed among a population-based cohort of 10,090 women treated for DCIS in the Netherlands between 1989 and 2004. Multivariable Cox regression analyses were used to evaluate associations of treatment with iIBC risk. Results Fifteen years after DCIS diagnosis, cumulative incidence of iIBC was 1.9 % after mastectomy, 8.8 % after BCS+RT, and 15.4 % after BCS alone. Patients treated with BCS alone had a higher iIBC risk than those treated with BCS+RT during the first 5 years after treatment. This difference was less pronounced for patients <50 years [hazard ratio (HR) 2.11, 95 % confidence interval (CI) 1.35–3.29 for women <50, and HR 4.44, 95 % CI 3.11–6.36 for women ≥50, P interaction  < 0.0001]. Beyond 5 years of follow-up, iIBC risk did not differ between patients treated with BCS+RT or BCS alone for women <50. Cumulative incidence of cIBC at 15 years was 6.4 %, compared to 3.4 % in the general population. Conclusions We report an interaction of treatment with age and follow-up period on iIBC risk, indicating that the benefit of RT seems to be smaller among younger women, and stressing the importance of clinical studies with long follow-up. Finally, the low cIBC risk does not justify contralateral prophylactic mastectomies for many women with unilateral DCIS.
To assess the effect of different treatment strategies on the risk of subsequent invasive breast cancer (IBC) in women diagnosed with ductal carcinoma in situ (DCIS). Up to 15-year cumulative incidences of ipsilateral IBC (iIBC) and contralateral IBC (cIBC) were assessed among a population-based cohort of 10,090 women treated for DCIS in the Netherlands between 1989 and 2004. Multivariable Cox regression analyses were used to evaluate associations of treatment with iIBC risk. Fifteen years after DCIS diagnosis, cumulative incidence of iIBC was 1.9 % after mastectomy, 8.8 % after BCS+RT, and 15.4 % after BCS alone. Patients treated with BCS alone had a higher iIBC risk than those treated with BCS+RT during the first 5 years after treatment. This difference was less pronounced for patients <50 years [hazard ratio (HR) 2.11, 95 % confidence interval (CI) 1.35-3.29 for women <50, and HR 4.44, 95 % CI 3.11-6.36 for women [greater than or equal to]50, P.sub.interaction < 0.0001]. Beyond 5 years of follow-up, iIBC risk did not differ between patients treated with BCS+RT or BCS alone for women <50. Cumulative incidence of cIBC at 15 years was 6.4 %, compared to 3.4 % in the general population. We report an interaction of treatment with age and follow-up period on iIBC risk, indicating that the benefit of RT seems to be smaller among younger women, and stressing the importance of clinical studies with long follow-up. Finally, the low cIBC risk does not justify contralateral prophylactic mastectomies for many women with unilateral DCIS.
Purpose To assess the effect of different treatment strategies on the risk of subsequent invasive breast cancer (IBC) in women diagnosed with ductal carcinoma in situ (DCIS). Methods Up to 15-year cumulative incidences of ipsilateral IBC (iIBC) and contralateral IBC (cIBC) were assessed among a population-based cohort of 10,090 women treated for DCIS in the Netherlands between 1989 and 2004. Multivariable Cox regression analyses were used to evaluate associations of treatment with iIBC risk. Results Fifteen years after DCIS diagnosis, cumulative incidence of iIBC was 1.9 % after mastectomy, 8.8 % after BCS+RT, and 15.4 % after BCS alone. Patients treated with BCS alone had a higher iIBC risk than those treated with BCS+RT during the first 5 years after treatment. This difference was less pronounced for patients <50 years [hazard ratio (HR) 2.11, 95 % confidence interval (CI) 1.35-3.29 for women <50, and HR 4.44, 95 % CI 3.11-6.36 for women [greater than or equal to]50, P.sub.interaction < 0.0001]. Beyond 5 years of follow-up, iIBC risk did not differ between patients treated with BCS+RT or BCS alone for women <50. Cumulative incidence of cIBC at 15 years was 6.4 %, compared to 3.4 % in the general population. Conclusions We report an interaction of treatment with age and follow-up period on iIBC risk, indicating that the benefit of RT seems to be smaller among younger women, and stressing the importance of clinical studies with long follow-up. Finally, the low cIBC risk does not justify contralateral prophylactic mastectomies for many women with unilateral DCIS.
Audience Academic
Author Rutgers, Emiel J.
van Leeuwen, Flora E.
Wesseling, Jelle
Schaapveld, Michael
Schmidt, Marjanka K.
Elshof, Lotte E.
Author_xml – sequence: 1
  givenname: Lotte E.
  surname: Elshof
  fullname: Elshof, Lotte E.
  organization: Department of Molecular Pathology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek, Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek, Department of Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek
– sequence: 2
  givenname: Michael
  surname: Schaapveld
  fullname: Schaapveld, Michael
  organization: Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek
– sequence: 3
  givenname: Marjanka K.
  surname: Schmidt
  fullname: Schmidt, Marjanka K.
  organization: Department of Molecular Pathology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek, Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek
– sequence: 4
  givenname: Emiel J.
  surname: Rutgers
  fullname: Rutgers, Emiel J.
  organization: Department of Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek
– sequence: 5
  givenname: Flora E.
  surname: van Leeuwen
  fullname: van Leeuwen, Flora E.
  organization: Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek
– sequence: 6
  givenname: Jelle
  surname: Wesseling
  fullname: Wesseling, Jelle
  email: j.wesseling@nki.nl
  organization: Department of Molecular Pathology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek, Department of Pathology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27624164$$D View this record in MEDLINE/PubMed
BookMark eNqNkttu1DAQhiNURA_wANwgS0iIC1LsnLzmAqmqOEmVuACurYkz6bpk7cV2ivYZeSkm2aVsK0AoFxnNfP_MaPwfZwfOO8yyx4KfCs7lyyh4XamciyYvlSzzzb3sSNQUyELIg-yICjJvFrw5zI5jvOKcK8nVg-ywkE1RiaY6yn58GtuI30Z0iQUbvzLfM7uOdoCEAQYGrmPGu0TxLmPdNUR7jawNCDExA85gYNBTmSXKpdXUrPeBdaNJpDAQjHV-BaRl0abxFQXGdkjCeUBaIsO-R5Om8QE66ykVYL2ZFMDWfj3SeOtd3kLEaaOlDzMs-AuuOPvuaejD7H4PQ8RHu_9J9uXtm8_n7_OLj-8-nJ9d5KbhIuVgoMRS1bWSRbXoOimqRhkBrTFCGtWqUkgBfY1tAZWqO16BIKgoe1EZWYryJHu97bse2xV2Bufz6HWwKwgb7cHq2xVnl_rSX-ua07vMDZ7vGgRPp49Jr2w0OAzg0I9Ri0UhVVnVSv0HKpTihawLQp_eQa_8GBxdYqa45LKsflOXMKC2rve0opma6rOKkGqheEnU6R8o-jpcWfID9pbytwTP9gRLhCEtox_G6dHibfDJ_vFurvbLkgSILWCCjzFgf4MIrifb663tNblbT7bXG9LIOxpj02wYWtsO_1QWW2WkKe4Sw97R_ir6CblLGG4
CODEN BCTRD6
CitedBy_id crossref_primary_10_1016_j_breast_2020_02_006
crossref_primary_10_1007_s12094_018_1994_1
crossref_primary_10_1097_SLA_0000000000002239
crossref_primary_10_1038_s41416_022_01888_2
crossref_primary_10_1016_j_breast_2022_03_006
crossref_primary_10_3390_cancers13030431
crossref_primary_10_1007_s10911_022_09517_7
crossref_primary_10_1038_s41698_024_00769_6
crossref_primary_10_1038_s41588_022_01082_3
crossref_primary_10_1177_1073274821997426
crossref_primary_10_1097_EDE_0000000000001423
crossref_primary_10_1158_1541_7786_MCR_20_0949
crossref_primary_10_1136_bmj_m1570
crossref_primary_10_1136_bmjopen_2022_061585
crossref_primary_10_1038_s41416_021_01496_6
crossref_primary_10_1016_j_clbc_2017_08_001
crossref_primary_10_1016_j_ejca_2018_06_027
crossref_primary_10_1016_j_trecan_2019_05_005
crossref_primary_10_3390_cancers15174397
crossref_primary_10_1186_s13058_017_0819_4
crossref_primary_10_2139_ssrn_3976873
crossref_primary_10_1001_jamaoncol_2024_0286
crossref_primary_10_1016_j_trecan_2023_01_002
crossref_primary_10_1038_s41523_021_00232_w
crossref_primary_10_1007_s10549_020_05816_x
crossref_primary_10_1002_cjp2_201
crossref_primary_10_1007_s10549_023_07168_8
crossref_primary_10_1055_a_2505_1682
crossref_primary_10_1080_14796694_2024_2421152
crossref_primary_10_1007_s10549_020_06055_w
crossref_primary_10_1097_PAS_0000000000001306
crossref_primary_10_1007_s10549_018_5048_8
crossref_primary_10_3390_biomedicines10051061
crossref_primary_10_1016_j_critrevonc_2019_04_016
crossref_primary_10_1001_jamaoncol_2024_2212
crossref_primary_10_1038_s41523_020_00202_8
crossref_primary_10_1136_bmj_2023_075498
crossref_primary_10_1038_s41416_024_02785_6
crossref_primary_10_3390_healthcare12070795
crossref_primary_10_1016_j_breast_2021_09_007
crossref_primary_10_1038_s41416_019_0478_6
crossref_primary_10_1038_s41416_021_01417_7
crossref_primary_10_1001_jamanetworkopen_2018_1100
crossref_primary_10_3390_cancers14225624
crossref_primary_10_1002_path_6289
crossref_primary_10_1159_000522244
crossref_primary_10_1038_s41568_022_00512_y
crossref_primary_10_1016_j_ctrv_2017_01_010
crossref_primary_10_1158_1078_0432_CCR_18_0201
crossref_primary_10_1016_j_cell_2023_07_024
Cites_doi 10.1200/JCO.2002.07.137
10.7326/M13-2548
10.1007/s10549-013-2813-6
10.1016/j.ijrobp.2007.03.062
10.1093/jncimonographs/lgq039
10.1200/JCO.2014.57.9029
10.1200/JCO.2008.20.1681
10.1200/JCO.2014.56.2595
10.1016/j.ejca.2015.05.008
10.1200/JCO.2013.49.5077
10.1016/j.surge.2014.02.005
10.1200/JCO.2015.60.8588
10.1186/bcr629
10.1093/jnci/djr027
10.1348/135910709X472174
10.1373/clinchem.2013.207183
10.1001/jamasurg.2015.0876
10.1016/S1470-2045(10)70266-7
10.1007/s10549-008-0067-5
10.1007/s10549-013-2455-8
10.1245/s10434-012-2413-4
10.1007/s10549-013-2539-5
10.1080/01621459.1999.10474144
10.1093/jnci/djg097
10.1093/jncimonographs/lgq022
10.1093/jncimonographs/lgq025
10.1148/radiol.12111461
10.1007/s10549-013-2670-3
10.1016/j.ijrobp.2008.06.1954
10.1245/s10434-014-4334-x
10.1016/j.jamcollsurg.2007.01.063
10.1093/jnci/dju156
10.1002/ijc.29452
10.1016/j.breast.2010.05.014
10.1007/s00330-007-0730-y
10.1007/s10549-011-1531-1
10.1002/cncr.20617
10.1007/s10434-999-0542-1
10.1093/jnci/94.20.1546
10.1093/jnci/djq499
10.1016/j.breast.2014.06.015
10.1001/jamaoncol.2015.2510
10.1001/jamainternmed.2015.3043
ContentType Journal Article
Copyright The Author(s) 2016
COPYRIGHT 2016 Springer
Springer Science+Business Media New York 2016
Copyright_xml – notice: The Author(s) 2016
– notice: COPYRIGHT 2016 Springer
– notice: Springer Science+Business Media New York 2016
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7X7
7XB
88E
8AO
8C1
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
H94
K9-
K9.
M0R
M0S
M1P
M2O
MBDVC
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
Q9U
7X8
5PM
DOI 10.1007/s10549-016-3973-y
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
AIDS and Cancer Research Abstracts
Consumer Health Database
ProQuest Health & Medical Complete (Alumni)
Consumer Health Database
ProQuest Health & Medical Collection
Medical Database
Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Pharma Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest Central Basic
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
Research Library Prep
MEDLINE - Academic
Oncogenes and Growth Factors Abstracts
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1573-7217
EndPage 563
ExternalDocumentID PMC5021731
4180654661
A470748903
27624164
10_1007_s10549_016_3973_y
Genre Journal Article
Feature
GrantInformation_xml – fundername: KWF Kankerbestrijding
  grantid: NKI2009-4363
  funderid: http://dx.doi.org/10.13039/501100004622
– fundername: Pink Ribbon
  grantid: 2011.WO19.C88
– fundername: ;
  grantid: NKI2009-4363
– fundername: ;
  grantid: 2011.WO19.C88
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-XW
-Y2
-~C
.86
.GJ
.VR
06C
06D
0R~
0VY
199
1N0
1SB
2.D
203
23N
28-
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
3O-
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5VS
67Z
6NX
78A
7X7
88E
8AO
8C1
8FI
8FJ
8G5
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHVE
ACHXU
ACIHN
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEAQA
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFDYV
AFEXP
AFFNX
AFJLC
AFKRA
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGVAE
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BKNYI
BPHCQ
BSONS
BVXVI
C6C
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
DWQXO
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNUQQ
GNWQR
GQ6
GQ7
GQ8
GRRUI
GUQSH
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IAO
ICW
IHE
IHR
IHW
IJ-
IKXTQ
IMOTQ
INH
INR
ITC
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
K9-
KDC
KOV
KOW
KPH
LAK
LLZTM
M0R
M1P
M2O
M4Y
MA-
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RNI
ROL
RPX
RRX
RSV
RZC
RZE
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UDS
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
YLTOR
Z45
Z7U
Z7W
Z81
Z82
Z83
Z87
Z8O
Z8Q
Z8U
Z8V
Z8W
Z91
ZGI
ZMTXR
ZOVNA
ZXP
~EX
~KM
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
ABRTQ
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
AEIIB
PMFND
7TO
7XB
8FK
H94
K9.
MBDVC
PKEHL
PQEST
PQUKI
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c601t-aca3e395597248dd71469c1abcc17c9b93171af5eb2a495d04a1d7123f14c7313
IEDL.DBID C6C
ISSN 0167-6806
1573-7217
IngestDate Thu Aug 21 13:42:25 EDT 2025
Thu Sep 04 16:25:56 EDT 2025
Thu Sep 04 20:25:44 EDT 2025
Sat Aug 16 08:51:30 EDT 2025
Tue Jun 17 21:12:35 EDT 2025
Tue Jun 10 20:14:48 EDT 2025
Thu May 22 21:22:32 EDT 2025
Mon Jul 21 05:55:43 EDT 2025
Tue Jul 01 03:37:52 EDT 2025
Thu Apr 24 23:08:59 EDT 2025
Fri Feb 21 02:31:49 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Invasive breast cancer
Ductal carcinoma in situ
Radiotherapy
Surgery
Population-based cohort study
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c601t-aca3e395597248dd71469c1abcc17c9b93171af5eb2a495d04a1d7123f14c7313
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doi.org/10.1007/s10549-016-3973-y
PMID 27624164
PQID 1819070734
PQPubID 36266
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5021731
proquest_miscellaneous_1827934599
proquest_miscellaneous_1819902752
proquest_journals_1819070734
gale_infotracmisc_A470748903
gale_infotracacademiconefile_A470748903
gale_healthsolutions_A470748903
pubmed_primary_27624164
crossref_primary_10_1007_s10549_016_3973_y
crossref_citationtrail_10_1007_s10549_016_3973_y
springer_journals_10_1007_s10549_016_3973_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-10-01
PublicationDateYYYYMMDD 2016-10-01
PublicationDate_xml – month: 10
  year: 2016
  text: 2016-10-01
  day: 01
PublicationDecade 2010
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: Netherlands
– name: Dordrecht
PublicationTitle Breast cancer research and treatment
PublicationTitleAbbrev Breast Cancer Res Treat
PublicationTitleAlternate Breast Cancer Res Treat
PublicationYear 2016
Publisher Springer US
Springer
Springer Nature B.V
Publisher_xml – name: Springer US
– name: Springer
– name: Springer Nature B.V
References Fine, Gray (CR30) 1999; 94
Alvarado, Lari, Roses (CR38) 2012; 19
Falk, Hofvind, Skaane, Haldorsen (CR15) 2011; 129
Collins, Achacoso, Haque (CR47) 2013; 139
Narod, Iqbal, Giannakeas (CR39) 2015
Wong, Chen, Gadd (CR21) 2014; 143
Piot-Ziegler, Sassi, Raffoul, Delaloye (CR45) 2010; 15
Van de Vijver, Peterse (CR1) 2003; 5
Bluekens, Holland, Karssemeijer (CR7) 2012; 265
Elshof, Tryfonidis, Slaets (CR49) 2015; 51
McCormick, Winter, Hudis (CR23) 2015; 33
Casparie, Tiebosch, Burger (CR28) 2007; 29
Tuttle, Jarosek, Habermann (CR40) 2009; 27
van Steenbergen, Voogd, Roukema (CR5) 2009; 115
Wapnir, Dignam, Fisher (CR25) 2011; 103
Correa, McGale (CR32) 2010; 2010
Holland, Peterse, Millis (CR29) 1994; 11
Solin, Gray, Hughes (CR22) 2015; 33
Rashtian, Iganej, Amy Liu, Natarajan (CR33) 2008; 72
CR8
Donker, Litière, Werutsky (CR24) 2013; 31
CR9
Sørum, Hofvind, Skaane, Haldorsen (CR4) 2010; 19
Vicini, Recht (CR35) 2002; 20
Schouten van der Velden, van Vugt, Van Dijck (CR18) 2007; 69
Ederer, Heise (CR31) 1959
Sagara, Mallory, Wong (CR10) 2015; 150
Ripping, Verbeek, Fracheboud (CR13) 2015; 137
Rakovitch, Nofech-Mozes, Narod (CR17) 2013; 138
Boekel, Schaapveld, Gietema (CR11) 2014; 106
Pradier, Cornuau, Norca (CR37) 2011; 31
Cuzick, Sestak, Pinder (CR27) 2011; 12
Rutter, Park, Killelea, Evans (CR42) 2015; 22
Sprague, McLaughlin, Hampton (CR16) 2013; 141
Harding, Pompei, Burmistrov (CR14) 2015
Kane, Virnig, Shamliyan (CR20) 2010; 2010
Montgomery, Tran, Heelan (CR44) 1999; 6
Goldflam, Hunt, Gershenwald (CR43) 2004; 101
CR50
Vigeland, Klaasen, Klingen (CR6) 2008; 18
Gierisch, Myers, Schmit (CR12) 2014; 160
Dick, Sorbero, Ahrendt (CR19) 2011; 103
Staley, McCallum, Bruce (CR46) 2014
Kerlikowske, Molinaro, Cha (CR48) 2003; 95
Bartlett, Nofech-Moses, Rakovitch (CR2) 2014; 60
Soran, Kamali Polat, Johnson, McGuire (CR41) 2014; 12
Ernster, Ballard-Barbash, Barlow (CR3) 2002; 94
Carlson, Page, Johnson (CR34) 2007; 204
Wärnberg, Garmo, Emdin (CR26) 2014; 32
Bijker, van Tienhoven (CR36) 2010; 2010
NB Boekel (3973_CR11) 2014; 106
IL Wapnir (3973_CR25) 2011; 103
TM Ripping (3973_CR13) 2015; 137
K Kerlikowske (3973_CR48) 2003; 95
J Cuzick (3973_CR27) 2011; 12
Y Sagara (3973_CR10) 2015; 150
JS Wong (3973_CR21) 2014; 143
A Soran (3973_CR41) 2014; 12
C Harding (3973_CR14) 2015
MJ Vijver Van de (3973_CR1) 2003; 5
F Wärnberg (3973_CR26) 2014; 32
SA Narod (3973_CR39) 2015
K Goldflam (3973_CR43) 2004; 101
H Staley (3973_CR46) 2014
JPG Fine (3973_CR30) 1999; 94
M Casparie (3973_CR28) 2007; 29
E Vigeland (3973_CR6) 2008; 18
AW Dick (3973_CR19) 2011; 103
A Rashtian (3973_CR33) 2008; 72
F Ederer (3973_CR31) 1959
GW Carlson (3973_CR34) 2007; 204
R Alvarado (3973_CR38) 2012; 19
3973_CR50
R Holland (3973_CR29) 1994; 11
RS Falk (3973_CR15) 2011; 129
AP Schouten van der Velden (3973_CR18) 2007; 69
LC Collins (3973_CR47) 2013; 139
AMJ Bluekens (3973_CR7) 2012; 265
C Piot-Ziegler (3973_CR45) 2010; 15
TM Tuttle (3973_CR40) 2009; 27
BL Sprague (3973_CR16) 2013; 141
C Correa (3973_CR32) 2010; 2010
VL Ernster (3973_CR3) 2002; 94
3973_CR8
LL Montgomery (3973_CR44) 1999; 6
3973_CR9
R Sørum (3973_CR4) 2010; 19
LN Steenbergen van (3973_CR5) 2009; 115
LJ Solin (3973_CR22) 2015; 33
N Bijker (3973_CR36) 2010; 2010
C Pradier (3973_CR37) 2011; 31
FA Vicini (3973_CR35) 2002; 20
JM Gierisch (3973_CR12) 2014; 160
LE Elshof (3973_CR49) 2015; 51
RL Kane (3973_CR20) 2010; 2010
M Donker (3973_CR24) 2013; 31
JMS Bartlett (3973_CR2) 2014; 60
B McCormick (3973_CR23) 2015; 33
E Rakovitch (3973_CR17) 2013; 138
CE Rutter (3973_CR42) 2015; 22
14625260 - J Natl Cancer Inst. 2003 Nov 19;95(22):1692-702
24262106 - Clin Chem. 2014 Jan;60(1):60-7
26291673 - JAMA Oncol. 2015 Oct;1(7):888-96
21617240 - Anticancer Res. 2011 May;31(5):1783-8
25128694 - J Natl Cancer Inst. 2014 Aug 15;106(8):null
10493622 - Ann Surg Oncol. 1999 Sep;6(6):546-52
19224844 - J Clin Oncol. 2009 Mar 20;27(9):1362-7
12381707 - J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54
21145284 - Lancet Oncol. 2011 Jan;12(1):21-9
21537936 - Breast Cancer Res Treat. 2011 Oct;129(3):929-38
24043739 - J Clin Oncol. 2013 Nov 10;31(32):4054-9
26147578 - JAMA Intern Med. 2015 Sep;175(9):1483-9
23624751 - Breast Cancer Res Treat. 2013 Jun;139(2):453-60
26039049 - JAMA Surg. 2015 Aug;150(8):739-45
17481544 - J Am Coll Surg. 2007 May;204(5):1074-8; discussion 1078-80
7831528 - Semin Diagn Pathol. 1994 Aug;11(3):167-80
25605856 - J Clin Oncol. 2015 Mar 1;33(7):709-15
27878644 - Breast Cancer Res Treat. 2017 Jan;161(2):389-390
24685410 - Surgeon. 2014 Dec;12(6):316-22
23033499 - Radiology. 2012 Dec;265(3):707-14
25612892 - Int J Cancer. 2015 Aug 15;137(4):921-9
25564175 - Ann Surg Oncol. 2015 Jul;22(7):2378-86
23979007 - Breast Cancer Res Treat. 2013 Aug;141(1):145-54
25311220 - J Clin Oncol. 2014 Nov 10;32(32):3613-8
24567146 - Ann Intern Med. 2014 Apr 1;160(7):484-91
24346130 - Breast Cancer Res Treat. 2014 Jan;143(2):343-50
22622473 - Ann Surg Oncol. 2012 Nov;19(12):3777-84
26025767 - Eur J Cancer. 2015 Aug;51(12):1497-510
20956824 - J Natl Cancer Inst Monogr. 2010;2010(41):162-77
20956816 - J Natl Cancer Inst Monogr. 2010;2010(41):130-3
12039936 - J Clin Oncol. 2002 Jun 1;20(11):2736-44
26371148 - J Clin Oncol. 2015 Nov 20;33(33):3938-44
18954711 - Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1016-20
21071225 - Breast. 2010 Dec;19(6):499-505
25023044 - Breast. 2014 Oct;23(5):546-51
19840495 - Br J Health Psychol. 2010 Sep;15(Pt 3):479-510
17544591 - Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):703-10
17680246 - Eur Radiol. 2008 Jan;18(1):183-91
18516674 - Breast Cancer Res Treat. 2009 May;115(1):181-3
21200025 - J Natl Cancer Inst. 2011 Jan 19;103(2):92-104
17429138 - Cell Oncol. 2007;29(1):19-24
21398619 - J Natl Cancer Inst. 2011 Mar 16;103(6):478-88
15389473 - Cancer. 2004 Nov 1;101(9):1977-86
12927038 - Breast Cancer Res. 2003;5(5):269
20956825 - J Natl Cancer Inst Monogr. 2010;2010(41):178-80
23456231 - Breast Cancer Res Treat. 2013 Apr;138(2):581-90
References_xml – volume: 20
  start-page: 2736
  year: 2002
  end-page: 2744
  ident: CR35
  article-title: Age at diagnosis and outcome for women with ductal carcinoma-in situ of the breast: a critical review of the literature
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2002.07.137
– volume: 160
  start-page: 484
  year: 2014
  end-page: 491
  ident: CR12
  article-title: Prioritization of research addressing management strategies for ductal carcinoma in situ
  publication-title: Ann Intern Med
  doi: 10.7326/M13-2548
– volume: 143
  start-page: 343
  year: 2014
  end-page: 350
  ident: CR21
  article-title: Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS)
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-013-2813-6
– volume: 69
  start-page: 703
  year: 2007
  end-page: 710
  ident: CR18
  article-title: Local recurrences after different treatment strategies for ductal carcinoma in situ of the breast: a population-based study in the East Netherlands
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2007.03.062
– year: 2014
  ident: CR46
  article-title: Postoperative tamoxifen for ductal carcinoma in situ: cochrane systematic review and meta-analysis
  publication-title: Breast
– volume: 31
  start-page: 1783
  year: 2011
  end-page: 1788
  ident: CR37
  article-title: Differences in breast carcinoma in situ between menopausal and premenopausal women
  publication-title: Anticancer Res
– volume: 2010
  start-page: 162
  year: 2010
  end-page: 177
  ident: CR32
  article-title: Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast early breast cancer trialists’ collaborative group (EBCTCG)
  publication-title: J Natl Cancer Inst Monogr
  doi: 10.1093/jncimonographs/lgq039
– volume: 33
  start-page: 709
  year: 2015
  end-page: 715
  ident: CR23
  article-title: RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.57.9029
– volume: 27
  start-page: 1362
  year: 2009
  end-page: 1367
  ident: CR40
  article-title: Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.20.1681
– volume: 32
  start-page: 3613
  issue: 32
  year: 2014
  end-page: 3618
  ident: CR26
  article-title: Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.56.2595
– volume: 51
  start-page: 1497
  year: 2015
  end-page: 1510
  ident: CR49
  article-title: Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ—The LORD study
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2015.05.008
– volume: 31
  start-page: 4054
  year: 2013
  end-page: 4059
  ident: CR24
  article-title: Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2013.49.5077
– volume: 29
  start-page: 19
  year: 2007
  end-page: 24
  ident: CR28
  article-title: Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive
  publication-title: Cell Oncol
– volume: 12
  start-page: 316
  year: 2014
  end-page: 322
  ident: CR41
  article-title: Increasing trend of contralateral prophylactic mastectomy: what are the factors behind this phenomenon?
  publication-title: Surgeon
  doi: 10.1016/j.surge.2014.02.005
– ident: CR8
– volume: 33
  start-page: 3938
  issue: 33
  year: 2015
  end-page: 3944
  ident: CR22
  article-title: Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2015.60.8588
– volume: 5
  start-page: 269
  year: 2003
  end-page: 275
  ident: CR1
  article-title: The diagnosis and management of pre-invasive breast disease: pathological diagnosis–problems with existing classifications
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr629
– volume: 103
  start-page: 478
  year: 2011
  end-page: 488
  ident: CR25
  article-title: Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djr027
– volume: 15
  start-page: 479
  year: 2010
  end-page: 510
  ident: CR45
  article-title: Mastectomy, body deconstruction, and impact on identity: a qualitative study
  publication-title: Br J Health Psychol
  doi: 10.1348/135910709X472174
– volume: 60
  start-page: 60
  year: 2014
  end-page: 67
  ident: CR2
  article-title: Ductal carcinoma in situ of the breast: can biomarkers improve current management?
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2013.207183
– volume: 150
  start-page: 739
  year: 2015
  end-page: 745
  ident: CR10
  article-title: Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study
  publication-title: JAMA Surg
  doi: 10.1001/jamasurg.2015.0876
– ident: CR50
– volume: 11
  start-page: 167
  year: 1994
  end-page: 180
  ident: CR29
  article-title: Ductal carcinoma in situ: a proposal for a new classification
  publication-title: Semin Diagn Pathol
– ident: CR9
– volume: 12
  start-page: 21
  year: 2011
  end-page: 29
  ident: CR27
  article-title: Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(10)70266-7
– volume: 115
  start-page: 181
  year: 2009
  end-page: 183
  ident: CR5
  article-title: Screening caused rising incidence rates of ductal carcinoma in situ of the breast
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-008-0067-5
– volume: 138
  start-page: 581
  year: 2013
  end-page: 590
  ident: CR17
  article-title: Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-013-2455-8
– volume: 19
  start-page: 3777
  year: 2012
  end-page: 3784
  ident: CR38
  article-title: Biology, treatment, and outcome in very young and older women with DCIS
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-012-2413-4
– volume: 139
  start-page: 453
  year: 2013
  end-page: 460
  ident: CR47
  article-title: Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-013-2539-5
– volume: 94
  start-page: 496
  year: 1999
  end-page: 509
  ident: CR30
  article-title: A proportional hazards model for the subdistribution of a competing risk
  publication-title: J Am Stat Assoc
  doi: 10.1080/01621459.1999.10474144
– volume: 95
  start-page: 1692
  year: 2003
  end-page: 1702
  ident: CR48
  article-title: Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djg097
– volume: 2010
  start-page: 130
  year: 2010
  end-page: 133
  ident: CR20
  article-title: The impact of surgery, radiation, and systemic treatment on outcomes in patients with ductal carcinoma in situ
  publication-title: J Natl Cancer Inst Monographs
  doi: 10.1093/jncimonographs/lgq022
– volume: 2010
  start-page: 178
  year: 2010
  end-page: 180
  ident: CR36
  article-title: Local and systemic outcomes in DCIS based on tumor and patient characteristics: the radiation oncologist’s perspective
  publication-title: J Natl Cancer Inst Monographs
  doi: 10.1093/jncimonographs/lgq025
– volume: 265
  start-page: 707
  year: 2012
  end-page: 714
  ident: CR7
  article-title: Comparison of digital screening mammography and screen-film mammography in the early detection of clinically relevant cancers: a multicenter study
  publication-title: Radiology
  doi: 10.1148/radiol.12111461
– volume: 141
  start-page: 145
  year: 2013
  end-page: 154
  ident: CR16
  article-title: Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-013-2670-3
– volume: 72
  start-page: 1016
  year: 2008
  end-page: 1020
  ident: CR33
  article-title: Close or positive margins after mastectomy for DCIS: pattern of relapse and potential indications for radiotherapy
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2008.06.1954
– year: 2015
  ident: CR14
  article-title: Breast cancer screening, incidence, and mortality across US counties
  publication-title: JAMA Intern Med
– year: 2015
  ident: CR39
  article-title: Breast cancer mortality after a diagnosis of ductal carcinoma in situ
  publication-title: JAMA Oncol
– volume: 22
  start-page: 2378
  year: 2015
  end-page: 2386
  ident: CR42
  article-title: Growing use of mastectomy for ductal carcinoma-in situ of the breast among young women in the united states
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-014-4334-x
– volume: 204
  start-page: 1074
  year: 2007
  end-page: 1078
  ident: CR34
  article-title: Local recurrence of ductal carcinoma in situ after skin-sparing mastectomy
  publication-title: J Am Coll Surg
  doi: 10.1016/j.jamcollsurg.2007.01.063
– volume: 106
  start-page: 156
  year: 2014
  ident: CR11
  article-title: Cardiovascular morbidity and mortality after treatment for ductal carcinoma in situ of the breast
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/dju156
– volume: 137
  start-page: 921
  year: 2015
  end-page: 929
  ident: CR13
  article-title: Overdiagnosis by mammographic screening for breast cancer studied in birth cohorts in The Netherlands
  publication-title: Int J Cancer
  doi: 10.1002/ijc.29452
– volume: 19
  start-page: 499
  year: 2010
  end-page: 505
  ident: CR4
  article-title: Trends in incidence of ductal carcinoma in situ: the effect of a population-based screening programme
  publication-title: Breast
  doi: 10.1016/j.breast.2010.05.014
– volume: 18
  start-page: 183
  year: 2008
  end-page: 191
  ident: CR6
  article-title: Full-field digital mammography compared to screen film mammography in the prevalent round of a population-based screening programme: the Vestfold County study
  publication-title: Eur Radiol
  doi: 10.1007/s00330-007-0730-y
– volume: 129
  start-page: 929
  year: 2011
  end-page: 938
  ident: CR15
  article-title: Second events following ductal carcinoma in situ of the breast: a register-based cohort study
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-011-1531-1
– volume: 101
  start-page: 1977
  year: 2004
  end-page: 1986
  ident: CR43
  article-title: Contralateral prophylactic mastectomy. Predictors of significant histologic findings
  publication-title: Cancer
  doi: 10.1002/cncr.20617
– volume: 6
  start-page: 546
  year: 1999
  end-page: 552
  ident: CR44
  article-title: Issues of regret in women with contralateral prophylactic mastectomies
  publication-title: Ann Surg Oncol
  doi: 10.1007/s10434-999-0542-1
– volume: 94
  start-page: 1546
  year: 2002
  end-page: 1554
  ident: CR3
  article-title: Detection of ductal carcinoma in situ in women undergoing screening mammography
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/94.20.1546
– year: 1959
  ident: CR31
  publication-title: Instructions to Ibm 650 programmers in processing survival computations. Technical end results evaluation section
– volume: 103
  start-page: 92
  year: 2011
  end-page: 104
  ident: CR19
  article-title: Comparative effectiveness of ductal carcinoma in situ management and the roles of margins and surgeons
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djq499
– volume: 103
  start-page: 478
  year: 2011
  ident: 3973_CR25
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djr027
– volume: 137
  start-page: 921
  year: 2015
  ident: 3973_CR13
  publication-title: Int J Cancer
  doi: 10.1002/ijc.29452
– volume: 2010
  start-page: 162
  year: 2010
  ident: 3973_CR32
  publication-title: J Natl Cancer Inst Monogr
  doi: 10.1093/jncimonographs/lgq039
– volume: 2010
  start-page: 130
  year: 2010
  ident: 3973_CR20
  publication-title: J Natl Cancer Inst Monographs
  doi: 10.1093/jncimonographs/lgq022
– ident: 3973_CR50
– volume: 95
  start-page: 1692
  year: 2003
  ident: 3973_CR48
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djg097
– ident: 3973_CR8
– volume: 27
  start-page: 1362
  year: 2009
  ident: 3973_CR40
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.20.1681
– volume: 19
  start-page: 499
  year: 2010
  ident: 3973_CR4
  publication-title: Breast
  doi: 10.1016/j.breast.2010.05.014
– volume: 160
  start-page: 484
  year: 2014
  ident: 3973_CR12
  publication-title: Ann Intern Med
  doi: 10.7326/M13-2548
– volume: 12
  start-page: 21
  year: 2011
  ident: 3973_CR27
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(10)70266-7
– volume: 31
  start-page: 1783
  year: 2011
  ident: 3973_CR37
  publication-title: Anticancer Res
– volume: 101
  start-page: 1977
  year: 2004
  ident: 3973_CR43
  publication-title: Cancer
  doi: 10.1002/cncr.20617
– volume: 18
  start-page: 183
  year: 2008
  ident: 3973_CR6
  publication-title: Eur Radiol
  doi: 10.1007/s00330-007-0730-y
– volume: 265
  start-page: 707
  year: 2012
  ident: 3973_CR7
  publication-title: Radiology
  doi: 10.1148/radiol.12111461
– volume: 69
  start-page: 703
  year: 2007
  ident: 3973_CR18
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2007.03.062
– volume: 51
  start-page: 1497
  year: 2015
  ident: 3973_CR49
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2015.05.008
– volume-title: Instructions to Ibm 650 programmers in processing survival computations. Technical end results evaluation section
  year: 1959
  ident: 3973_CR31
– volume: 2010
  start-page: 178
  year: 2010
  ident: 3973_CR36
  publication-title: J Natl Cancer Inst Monographs
  doi: 10.1093/jncimonographs/lgq025
– volume: 19
  start-page: 3777
  year: 2012
  ident: 3973_CR38
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-012-2413-4
– volume: 33
  start-page: 709
  year: 2015
  ident: 3973_CR23
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.57.9029
– volume: 60
  start-page: 60
  year: 2014
  ident: 3973_CR2
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2013.207183
– volume: 129
  start-page: 929
  year: 2011
  ident: 3973_CR15
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-011-1531-1
– volume: 33
  start-page: 3938
  issue: 33
  year: 2015
  ident: 3973_CR22
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2015.60.8588
– volume: 22
  start-page: 2378
  year: 2015
  ident: 3973_CR42
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-014-4334-x
– volume: 143
  start-page: 343
  year: 2014
  ident: 3973_CR21
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-013-2813-6
– volume: 11
  start-page: 167
  year: 1994
  ident: 3973_CR29
  publication-title: Semin Diagn Pathol
– ident: 3973_CR9
– year: 2014
  ident: 3973_CR46
  publication-title: Breast
  doi: 10.1016/j.breast.2014.06.015
– volume: 115
  start-page: 181
  year: 2009
  ident: 3973_CR5
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-008-0067-5
– volume: 31
  start-page: 4054
  year: 2013
  ident: 3973_CR24
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2013.49.5077
– volume: 29
  start-page: 19
  year: 2007
  ident: 3973_CR28
  publication-title: Cell Oncol
– volume: 15
  start-page: 479
  year: 2010
  ident: 3973_CR45
  publication-title: Br J Health Psychol
  doi: 10.1348/135910709X472174
– volume: 12
  start-page: 316
  year: 2014
  ident: 3973_CR41
  publication-title: Surgeon
  doi: 10.1016/j.surge.2014.02.005
– volume: 139
  start-page: 453
  year: 2013
  ident: 3973_CR47
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-013-2539-5
– volume: 5
  start-page: 269
  year: 2003
  ident: 3973_CR1
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr629
– year: 2015
  ident: 3973_CR39
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2015.2510
– volume: 103
  start-page: 92
  year: 2011
  ident: 3973_CR19
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djq499
– volume: 138
  start-page: 581
  year: 2013
  ident: 3973_CR17
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-013-2455-8
– volume: 6
  start-page: 546
  year: 1999
  ident: 3973_CR44
  publication-title: Ann Surg Oncol
  doi: 10.1007/s10434-999-0542-1
– volume: 204
  start-page: 1074
  year: 2007
  ident: 3973_CR34
  publication-title: J Am Coll Surg
  doi: 10.1016/j.jamcollsurg.2007.01.063
– volume: 72
  start-page: 1016
  year: 2008
  ident: 3973_CR33
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2008.06.1954
– volume: 94
  start-page: 496
  year: 1999
  ident: 3973_CR30
  publication-title: J Am Stat Assoc
  doi: 10.1080/01621459.1999.10474144
– volume: 32
  start-page: 3613
  issue: 32
  year: 2014
  ident: 3973_CR26
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.56.2595
– volume: 150
  start-page: 739
  year: 2015
  ident: 3973_CR10
  publication-title: JAMA Surg
  doi: 10.1001/jamasurg.2015.0876
– volume: 20
  start-page: 2736
  year: 2002
  ident: 3973_CR35
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2002.07.137
– volume: 94
  start-page: 1546
  year: 2002
  ident: 3973_CR3
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/94.20.1546
– year: 2015
  ident: 3973_CR14
  publication-title: JAMA Intern Med
  doi: 10.1001/jamainternmed.2015.3043
– volume: 141
  start-page: 145
  year: 2013
  ident: 3973_CR16
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-013-2670-3
– volume: 106
  start-page: 156
  year: 2014
  ident: 3973_CR11
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/dju156
– reference: 21145284 - Lancet Oncol. 2011 Jan;12(1):21-9
– reference: 23033499 - Radiology. 2012 Dec;265(3):707-14
– reference: 23979007 - Breast Cancer Res Treat. 2013 Aug;141(1):145-54
– reference: 19840495 - Br J Health Psychol. 2010 Sep;15(Pt 3):479-510
– reference: 24262106 - Clin Chem. 2014 Jan;60(1):60-7
– reference: 25605856 - J Clin Oncol. 2015 Mar 1;33(7):709-15
– reference: 14625260 - J Natl Cancer Inst. 2003 Nov 19;95(22):1692-702
– reference: 24346130 - Breast Cancer Res Treat. 2014 Jan;143(2):343-50
– reference: 25612892 - Int J Cancer. 2015 Aug 15;137(4):921-9
– reference: 18516674 - Breast Cancer Res Treat. 2009 May;115(1):181-3
– reference: 26371148 - J Clin Oncol. 2015 Nov 20;33(33):3938-44
– reference: 25564175 - Ann Surg Oncol. 2015 Jul;22(7):2378-86
– reference: 21200025 - J Natl Cancer Inst. 2011 Jan 19;103(2):92-104
– reference: 12927038 - Breast Cancer Res. 2003;5(5):269
– reference: 27878644 - Breast Cancer Res Treat. 2017 Jan;161(2):389-390
– reference: 12381707 - J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54
– reference: 25311220 - J Clin Oncol. 2014 Nov 10;32(32):3613-8
– reference: 12039936 - J Clin Oncol. 2002 Jun 1;20(11):2736-44
– reference: 24567146 - Ann Intern Med. 2014 Apr 1;160(7):484-91
– reference: 17544591 - Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):703-10
– reference: 23456231 - Breast Cancer Res Treat. 2013 Apr;138(2):581-90
– reference: 22622473 - Ann Surg Oncol. 2012 Nov;19(12):3777-84
– reference: 24043739 - J Clin Oncol. 2013 Nov 10;31(32):4054-9
– reference: 15389473 - Cancer. 2004 Nov 1;101(9):1977-86
– reference: 26147578 - JAMA Intern Med. 2015 Sep;175(9):1483-9
– reference: 21537936 - Breast Cancer Res Treat. 2011 Oct;129(3):929-38
– reference: 7831528 - Semin Diagn Pathol. 1994 Aug;11(3):167-80
– reference: 23624751 - Breast Cancer Res Treat. 2013 Jun;139(2):453-60
– reference: 26025767 - Eur J Cancer. 2015 Aug;51(12):1497-510
– reference: 19224844 - J Clin Oncol. 2009 Mar 20;27(9):1362-7
– reference: 10493622 - Ann Surg Oncol. 1999 Sep;6(6):546-52
– reference: 17481544 - J Am Coll Surg. 2007 May;204(5):1074-8; discussion 1078-80
– reference: 17429138 - Cell Oncol. 2007;29(1):19-24
– reference: 18954711 - Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1016-20
– reference: 26291673 - JAMA Oncol. 2015 Oct;1(7):888-96
– reference: 25128694 - J Natl Cancer Inst. 2014 Aug 15;106(8):null
– reference: 21398619 - J Natl Cancer Inst. 2011 Mar 16;103(6):478-88
– reference: 21071225 - Breast. 2010 Dec;19(6):499-505
– reference: 17680246 - Eur Radiol. 2008 Jan;18(1):183-91
– reference: 21617240 - Anticancer Res. 2011 May;31(5):1783-8
– reference: 25023044 - Breast. 2014 Oct;23(5):546-51
– reference: 20956825 - J Natl Cancer Inst Monogr. 2010;2010(41):178-80
– reference: 24685410 - Surgeon. 2014 Dec;12(6):316-22
– reference: 20956824 - J Natl Cancer Inst Monogr. 2010;2010(41):162-77
– reference: 26039049 - JAMA Surg. 2015 Aug;150(8):739-45
– reference: 20956816 - J Natl Cancer Inst Monogr. 2010;2010(41):130-3
SSID ssj0009709
Score 2.423729
Snippet Purpose To assess the effect of different treatment strategies on the risk of subsequent invasive breast cancer (IBC) in women diagnosed with ductal carcinoma...
To assess the effect of different treatment strategies on the risk of subsequent invasive breast cancer (IBC) in women diagnosed with ductal carcinoma in situ...
Purpose To assess the effect of different treatment strategies on the risk of subsequent invasive breast cancer (IBC) in women diagnosed with ductal carcinoma...
SourceID pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 553
SubjectTerms Aged
Breast cancer
Breast Neoplasms - epidemiology
Breast Neoplasms - radiotherapy
Breast Neoplasms - surgery
Cancer research
Cancer therapies
Cancer treatment
Carcinoma
Carcinoma, Ductal, Breast - epidemiology
Carcinoma, Intraductal, Noninfiltrating - radiotherapy
Carcinoma, Intraductal, Noninfiltrating - surgery
Cohort Studies
College football
Disease-Free Survival
Drug therapy
Epidemiology
Female
Health aspects
Humans
Incidence
Mastectomy - adverse effects
Mastectomy - methods
Mastectomy, Segmental - adverse effects
Mastectomy, Segmental - methods
Medicine
Medicine & Public Health
Middle Aged
Multimodal Imaging
Netherlands - epidemiology
Oncology
Proportional Hazards Models
Radiation therapy
Radiotherapy
Risk factors
Treatment Outcome
Women
SummonAdditionalLinks – databaseName: Public Health Database
  dbid: 8C1
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgifls9NYIgqMGmST_iixyHxyGcTx7cW0mTlCus7brbFfZv9J9yJk271wX3tZmQNJnMR_KbGULeWZNIMNoEs4VyTOrasMpYw1wqXaElV85Xb7j4kZ1fyu9X6VW4cFsHWOUoE72gtp3BO_LPHFVXDgwpvy5_M6waha-roYTGbXIHY0DR-SpOdxAPlQ8QD8ztnRVxNr5qDqFz4BmBI50x0MiCbWd6aV8631BP-9DJvfdTr5bOHpD7wZ6kJwMDPCS3XPuI3L0IL-aPyV-UDB4u3VOEkdOups1y3Sw0hh4vqG4t9XB1PX5p2j8aMe20Qrx6Tw3yxYr6YuJ0wqVTMHYp5oqFHgbrEbXdLw19KazX5gvFG3xfrdQPAEYmHYAjOPxK2ybEfW2xh6bLqYoYQ62KM7oGtwCJefwpVjH1iSKekMuzbz9Pz1ko4MAM-Hk900YLJ3yOu0QW1uYglpXhujKG50ZVCowXrusUvHsNjpqNpeZAlIiaS5MLLp6So7Zr3XNCNWwXfM25ycAgsUbVYEqBrZK7GBhK8IjE4_aVJmQ3xyIbi3KXlxl3vEREG-54uY3Ih6nLckjtcYj4DfJEOUSnTmKhPJHAk7JQsYjIe0-BggFGNjrEN8D8McXWjPJ4RgkH2sybR74rg0BZlzv2j8jbqRl7Ikiudd1moFH4DJ0coklAIstUqYg8G1h5-vkEFCPY5zBCPmPyiQBTkc9b2ubapyRP0bXFXfg4HocbU__fmr44_KMvyb0Ez6dHTh6To361ca_AAuyr1_6Y_wPdnFnZ
  priority: 102
  providerName: ProQuest
Title Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women
URI https://link.springer.com/article/10.1007/s10549-016-3973-y
https://www.ncbi.nlm.nih.gov/pubmed/27624164
https://www.proquest.com/docview/1819070734
https://www.proquest.com/docview/1819902752
https://www.proquest.com/docview/1827934599
https://pubmed.ncbi.nlm.nih.gov/PMC5021731
Volume 159
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swEBdrC2MvY99112UaDAbbDJYtW9bekpCsbDSMsUD2ZGRZpobMCYlTyN-4f2p38kfrsBX2YoN1ipTc-T6iu98R8jbTPgenLXCzWBqXq1y7qc60a0JuYsWZNLZ7w-UsupjzL4tw0YBFYy3Mwfk9lrhBBAMBb-SC5Qzc_RE5CUHvojCPo_ENvq6oszkQxjuKvag9wPzbR_RM0KEivmWJDrMkD45KrQWaPiIPG9eRDmtePyb3TPmE3L9sDsefkt-oBGxmdEUxY5yuclqst8VSYZXxkqoyozYzXbVPivJaYfo6TTE1vaIaRWBDbd9w2qWgU_BrKcLCwgyNrYfK1S8Fc-m2qHafKP5ZbxuT2gXAn6R1jgguv1FZ0ZR47XGGouuuYZiLBhR3dAURABIz76MnPWoxIZ6R-XTyY3zhNr0aXA0hXeUqrQITWDg7n8dZJkADS81UqjUTWqYS_BSm8hACeQUxWeZxxYDID3LGtQhY8Jwcl6vSnBKqgF3wVDAdge-RaZmD1wRuiTAeyE7AHOK17Et0A2SO_TSWyQ0EM3I8weQ15Hiyd8j7bsq6RvG4i_g1ykRSF6J2GiAZcuEhVo8XOOSdpUAdACtr1ZQywP4RTatHed6jhHdX94dbuUsa3bFNGDppQBFwh7zphnEm5sOVZrWraSSeOPt30figfHkopUNe1KLcfXkfbCC44rCC6Al5R4Co4_2Rsriy6OMhRrHIhQ_t63Br6__6Tc_-i_oleeDj62pzJs_JcbXZmVfg-1XpgByJhYBrPGYDcjKcjkYzvH_--XUC99Fk9u37wGoGuM794R8EflpW
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbhMxEB2VVAJeEHcChRoJhARYrHed7BqpQgVapbSJEGqlvi2O7aiRwibkAsrP8QP8FDPeS7qRyFtf1-PYmxnPZX1mBuCFNaFEpy3iNlGOSz0wvG-s4a4lXaKlUM53b-j22p0z-eW8db4Ff8pcGIJVljrRK2o7NvSN_J0g0xWjQMoPk5-cukbR7WrZQkMXrRXsni8xViR2HLvlbwzhZntHn5HfL8Pw8OD0U4cXXQa4wWBkzrXRkYt8IbZQJtbGqDuUEbpvjIiN6iu0sEIPWhiCaowmbCC1QKIwGghp4khE-LvXYFvSB5QGbH886H39tir7G-cgE6ou3k6CdnmvmifvYWyGoXybo08Q8WXNMq7bh0sGch28uXaD6w3j4W24VXi0bD8XwTuw5bK7cL1b3Nnfg7-kmzxge84IyM7GAzaczIYjTcnPI6YzyzxgXpdPhtkvTah61ifE_JwZkswp8-3MWYWMZ-huM6pWizMMdUTKxj80zmXIscV7RncIvl-qXwDdXJZDV2j5qbbDIvNsSTM0m1R9zDjZddrRBQYmRCyCt4EKmC9VcR_OroS5D6CRjTP3CJhGduHTWJg2ukTWqAE6c-gtxS5AkY5EE4KSfakp6qtTm49RuqoMTRxPCVNHHE-XTXhdTZnkxUU2Ee-STKR5fmylmNJ9iadCJiqImvDKU5BqwpWNLjIscP9U5KtGuVOjRJVi6sOl3KWFSpulqwPYhOfVMM0kmF7mxoucRtFFeLiJJkSbIFtKNeFhLsrVy4domjFCwBXimpBXBFQMvT6SDS98UfQWBdfEhTflcbi09f_9p483v-gu3Oicdk_Sk6Pe8RO4GdJZ9TjOHWjMpwv3FP3Ref9ZcegZfL9qPfMPK1Ccxg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGJk28IL7pGMxIICTAWpw4TY00ocFWbYxVE2LS3jLXdrRKXVL6Aeq_CP8Ud46TLpXo217jc-30zvcR_-6OkNdGhwKctoiZjrRMqEyzvjaa2VjYjhJcWte94bTXPjoXXy_iizXyp8qFQVhlpROdojaFxm_kuxxNVwICKXYzD4s4O-h-Gv1k2EEKb1qrdhrKt1kwe67cmE_yOLHz3xDOTfaOD4D3b8Kwe_jjyxHzHQeYhsBkypRWkY1cUbZQdIxJQI9IzVVfa55o2ZdgbbnKYghHFUQWJhCKA1EYZVzoJOIR_O4dspGA1YdAcOPzYe_s-6IEcFICTrDSeLsTtKs71jKRD-I0COvbDPyDiM0bVnLZVtwwlstAzqXbXGcku_fJPe_d0v1SHB-QNZs_JJun_v7-EfmLesqBt6cUQe20yOhgNBkMFSZCD6nKDXXgeVU9GeS_FCLsaR_R81OqUUrH1LU2pzVKnoLrTbFyLczQ2B0pL64VzKXAsdlHivcJrneqWwBcXlrCWHD5sTIDn4U2xxmKjuqeZgxtPO7oCoIUJObBh0AG1JWteEzOb4W5T8h6XuT2GaEK2AVPE67b4B4ZLTNw7MBzSmwA4h3xFgkq9qXa11rHlh_DdFElGjmeIr4OOZ7OW-RdPWVUFhpZRbyDMpGWubK1kkr3BZwQ0ZFB1CJvHQWqKVhZK59tAfvHgl8Nyu0GJagX3Ryu5C716m2SLg5ji7yqh3EmQvZyW8xKGomX4uEqmhDsg4ilbJGnpSjXLx-CmYZoAVZIGkJeE2Bh9OZIPrhyBdJjDLSRC--r43Bj6__7T7dWv-gO2QR9k3477p08J3dDPKoO0rlN1qfjmX0Brum0_9KfeUoub1vN_APu6KEK
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Subsequent+risk+of+ipsilateral+and+contralateral+invasive+breast+cancer+after+treatment+for+ductal+carcinoma+in+situ%3A+incidence+and+the+effect+of+radiotherapy+in+a+population-based+cohort+of+10%2C090+women&rft.jtitle=Breast+cancer+research+and+treatment&rft.au=Elshof%2C+Lotte+E.&rft.au=Schaapveld%2C+Michael&rft.au=Schmidt%2C+Marjanka+K.&rft.au=Rutgers%2C+Emiel+J.&rft.date=2016-10-01&rft.pub=Springer+US&rft.issn=0167-6806&rft.eissn=1573-7217&rft.volume=159&rft.issue=3&rft.spage=553&rft.epage=563&rft_id=info:doi/10.1007%2Fs10549-016-3973-y&rft_id=info%3Apmid%2F27624164&rft.externalDocID=PMC5021731
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-6806&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-6806&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-6806&client=summon